New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:41 EDTBMYBristol-Myers announces follow up results from Study -004
Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab, an investigational PD-1 immune checkpoint inhibitor, and Yervoy given either concurrently or sequentially in patients with advanced melanoma. After an additional year of follow up of the cohort that received the concurrent combination regimen of nivolumab 1 mg/kg plus Yervoy 3mg/kg, the one-year overall survival rate was 94% and the two-year OS rate was 88%. These are the doses used in the ongoing Phase 2 and Phase 3 trials, CheckMate -069 and -067. No new safety signals were reported in the concurrent combination cohorts with additional follow up and grade 3-4 treatment-related adverse events occurred in 62% of patients. The most common were asymptomatic increases in lipase, ALT and AST. These data will be presented today at the 50th Annual Meeting of the American Society of Clinical Oncology and featured during an ASCO press briefing at 8 a.m. CDT.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
07:21 EDTBMYEBD Group to hold a conference
Subscribe for More Information
September 17, 2014
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use